{"id":35785,"date":"2019-03-12T11:27:00","date_gmt":"2019-03-12T11:27:00","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=35785"},"modified":"2019-03-13T10:52:43","modified_gmt":"2019-03-13T10:52:43","slug":"i-base-fit-for-purpose-report-launched-at-croi-2019","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/35785","title":{"rendered":"i-Base Fit for Purpose report launched at CROI 2019"},"content":{"rendered":"<p><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-35786\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/03\/FFP-cover-208x300.png\" alt=\"\" width=\"208\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/03\/FFP-cover-208x300.png 208w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/03\/FFP-cover-768x1107.png 768w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/03\/FFP-cover-710x1024.png 710w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/03\/FFP-cover.png 1394w\" sizes=\"auto, (max-width: 208px) 100vw, 208px\" \/>Fit for Purpose provides an overview of recent developments in antiretroviral treatment (ART) optimisation for HIV positive adults, in low- and middle-income countries (LMICs).<\/strong><\/p>\n<p>We produce Fit for Purpose annually for distribution at the International AIDS Society (IAS) conferences, with updates to coincide with other key HIV meetings.<\/p>\n<p>This abbreviated version \u2013 looking at optimised ART for adults and including the HIV pipeline \u2013 was released at the annual Conference on Retroviruses and Opportunistic Infections (CROI) 2019<\/p>\n<p>Key developments since the July 2018 edition include:<\/p>\n<ul>\n<li>Interim World Health Organisation guidelines recommending dolutegravir (DTG)-based regimens for all adults and children (for whom approved DTG dosing is available) as preferred first- and second-line ART \u2013 published December 2018<\/li>\n<li>Week 48 results from the NAMSAL study \u2013 a key ART optimisation trial of first-line DTG vs efavirenz (EFV) in an African setting \u2013 presented October 2018<\/li>\n<li>Week 48 results from a second-line switch study of people stable on a twice-daily lopinavir\/ritonavir (LPV\/r)-based regimen who switched to a once-daily 400\/100 mg darunavir\/ritonavir (DRV\/r) one \u2013 presented July 2018<\/li>\n<li>Pharmacokinetic data on tenofovir alafenamide (TAF) pregnancy from IMPAACT P1026s \u2013 presented July 2018<\/li>\n<\/ul>\n<p>We will continue to cover key developments in optimised ART and new drugs and strategies in HTB throughout the year.<\/p>\n<p>The July 2019 update will include ART optimisation for both adults and children and a new section on long acting formulations<\/p>\n<p><a href=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/03\/iBase-fitforpurpose-march2019.pdf\">Download Fit for Purpose<\/a>\u00a0(March 2019)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fit for Purpose provides an overview of recent developments in antiretroviral treatment (ART) optimisation for HIV positive adults, in low- and middle-income countries (LMICs). We produce Fit for Purpose annually for distribution at the International AIDS Society (IAS) conferences, with &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[162,4],"tags":[264],"class_list":["post-35785","post","type-post","status-publish","format-standard","hentry","category-supplements","category-conference-reports","tag-croi-2019"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/35785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=35785"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/35785\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=35785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=35785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=35785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}